187 related articles for article (PubMed ID: 15743192)
1. Dynamic receptor-based pharmacophore model development and its application in designing novel HIV-1 integrase inhibitors.
Deng J; Lee KW; Sanchez T; Cui M; Neamati N; Briggs JM
J Med Chem; 2005 Mar; 48(5):1496-505. PubMed ID: 15743192
[TBL] [Abstract][Full Text] [Related]
2. Dynamic pharmacophore model optimization: identification of novel HIV-1 integrase inhibitors.
Deng J; Sanchez T; Neamati N; Briggs JM
J Med Chem; 2006 Mar; 49(5):1684-92. PubMed ID: 16509584
[TBL] [Abstract][Full Text] [Related]
3. Pharmacophore-based design of HIV-1 integrase strand-transfer inhibitors.
Barreca ML; Ferro S; Rao A; De Luca L; Zappalà M; Monforte AM; Debyser Z; Witvrouw M; Chimirri A
J Med Chem; 2005 Nov; 48(22):7084-8. PubMed ID: 16250669
[TBL] [Abstract][Full Text] [Related]
4. A platform for designing HIV integrase inhibitors. Part 1: 2-hydroxy-3-heteroaryl acrylic acid derivatives as novel HIV integrase inhibitor and modeling of hydrophilic and hydrophobic pharmacophores.
Kawasuji T; Yoshinaga T; Sato A; Yodo M; Fujiwara T; Kiyama R
Bioorg Med Chem; 2006 Dec; 14(24):8430-45. PubMed ID: 17010623
[TBL] [Abstract][Full Text] [Related]
5. Exploring binding mode for styrylquinoline HIV-1 integrase inhibitors using comparative molecular field analysis and docking studies.
Ma XH; Zhang XY; Tan JJ; Chen WZ; Wang CX
Acta Pharmacol Sin; 2004 Jul; 25(7):950-8. PubMed ID: 15210071
[TBL] [Abstract][Full Text] [Related]
6. Salicylhydrazine-containing inhibitors of HIV-1 integrase: implication for a selective chelation in the integrase active site.
Neamati N; Hong H; Owen JM; Sunder S; Winslow HE; Christensen JL; Zhao H; Burke TR; Milne GW; Pommier Y
J Med Chem; 1998 Aug; 41(17):3202-9. PubMed ID: 9703465
[TBL] [Abstract][Full Text] [Related]
7. Discovery of HIV-1 integrase inhibitors by pharmacophore searching.
Hong H; Neamati N; Wang S; Nicklaus MC; Mazumder A; Zhao H; Burke TR; Pommier Y; Milne GW
J Med Chem; 1997 Mar; 40(6):930-6. PubMed ID: 9083481
[TBL] [Abstract][Full Text] [Related]
8. Beta-diketo acid pharmacophore hypothesis. 1. Discovery of a novel class of HIV-1 integrase inhibitors.
Dayam R; Sanchez T; Clement O; Shoemaker R; Sei S; Neamati N
J Med Chem; 2005 Jan; 48(1):111-20. PubMed ID: 15634005
[TBL] [Abstract][Full Text] [Related]
9. Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors.
Chen X; Tsiang M; Yu F; Hung M; Jones GS; Zeynalzadegan A; Qi X; Jin H; Kim CU; Swaminathan S; Chen JM
J Mol Biol; 2008 Jul; 380(3):504-19. PubMed ID: 18565342
[TBL] [Abstract][Full Text] [Related]
10. A platform for designing HIV integrase inhibitors. Part 2: a two-metal binding model as a potential mechanism of HIV integrase inhibitors.
Kawasuji T; Fuji M; Yoshinaga T; Sato A; Fujiwara T; Kiyama R
Bioorg Med Chem; 2006 Dec; 14(24):8420-9. PubMed ID: 17005407
[TBL] [Abstract][Full Text] [Related]
11. Tn5 transposase as a useful platform to simulate HIV-1 integrase inhibitor binding mode.
Barreca ML; Ortuso F; Iraci N; De Luca L; Alcaro S; Chimirri A
Biochem Biophys Res Commun; 2007 Nov; 363(3):554-60. PubMed ID: 17889829
[TBL] [Abstract][Full Text] [Related]
12. Diketo acid pharmacophore. 2. Discovery of structurally diverse inhibitors of HIV-1 integrase.
Dayam R; Sanchez T; Neamati N
J Med Chem; 2005 Dec; 48(25):8009-15. PubMed ID: 16335925
[TBL] [Abstract][Full Text] [Related]
13. Discovery of structurally diverse HIV-1 integrase inhibitors based on a chalcone pharmacophore.
Deng J; Sanchez T; Al-Mawsawi LQ; Dayam R; Yunes RA; Garofalo A; Bolger MB; Neamati N
Bioorg Med Chem; 2007 Jul; 15(14):4985-5002. PubMed ID: 17502148
[TBL] [Abstract][Full Text] [Related]
14. Rational design of 2-pyrrolinones as inhibitors of HIV-1 integrase.
Ma K; Wang P; Fu W; Wan X; Zhou L; Chu Y; Ye D
Bioorg Med Chem Lett; 2011 Nov; 21(22):6724-7. PubMed ID: 21996518
[TBL] [Abstract][Full Text] [Related]
15. Application of CoMFA and CoMSIA 3D-QSAR and docking studies in optimization of mercaptobenzenesulfonamides as HIV-1 integrase inhibitors.
Kuo CL; Assefa H; Kamath S; Brzozowski Z; Slawinski J; Saczewski F; Buolamwini JK; Neamati N
J Med Chem; 2004 Jan; 47(2):385-99. PubMed ID: 14711310
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of novel dihydroquinoline-3-carboxylic acids as HIV-1 integrase inhibitors.
Sechi M; Rizzi G; Bacchi A; Carcelli M; Rogolino D; Pala N; Sanchez TW; Taheri L; Dayam R; Neamati N
Bioorg Med Chem; 2009 Apr; 17(7):2925-35. PubMed ID: 19026554
[TBL] [Abstract][Full Text] [Related]
17. Triketoacid inhibitors of HIV-integrase: a new chemotype useful for probing the integrase pharmacophore.
Walker MA; Johnson T; Ma Z; Banville J; Remillard R; Kim O; Zhang Y; Staab A; Wong H; Torri A; Samanta H; Lin Z; Deminie C; Terry B; Krystal M; Meanwell N
Bioorg Med Chem Lett; 2006 Jun; 16(11):2920-4. PubMed ID: 16546383
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 integrase pharmacophore: discovery of inhibitors through three-dimensional database searching.
Nicklaus MC; Neamati N; Hong H; Mazumder A; Sunder S; Chen J; Milne GW; Pommier Y
J Med Chem; 1997 Mar; 40(6):920-9. PubMed ID: 9083480
[TBL] [Abstract][Full Text] [Related]
19. Dissecting Tn5 transposition using HIV-1 integrase diketoacid inhibitors.
Czyz A; Stillmock KA; Hazuda DJ; Reznikoff WS
Biochemistry; 2007 Sep; 46(38):10776-89. PubMed ID: 17725323
[TBL] [Abstract][Full Text] [Related]
20. Active site binding modes of the beta-diketoacids: a multi-active site approach in HIV-1 integrase inhibitor design.
Dayam R; Neamati N
Bioorg Med Chem; 2004 Dec; 12(24):6371-81. PubMed ID: 15556755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
